FDA shares additional draft guidance on cell and gene therapy

The US Food and Drug Administration (FDA) has published new draft guidance around the development and application process for new cell or gene therapies (CGTs).

The draft is an extension of previous guidance published in January 2020 on the chemistry, manufacturing and control information for human gene therapy investigational new drug (IND) applications.